ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / VSTM / insiders
AMPH (72) RAPP (30) SNDX (17) SLN (44) ⌘ Pro Terminal β†’

Verastem Inc. (VSTM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.59 -1.64% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.54

Verastem Inc. (VSTM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $1.18B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VSTM Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Verastem Inc. (NASDAQ: VSTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.59 (-1.64% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VSTM ranks #561 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does VSTM compare to AMPH and RAPP in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, AMPH (Amphastar Pharmaceuticals Inc.) holds a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VSTM?
β–Ό

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.54 (-0.49%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk E
Cash (4)Whales (16)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$11 Bull$9 Base$7 Bear
πŸ“¬ FREE VSTM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for VSTM)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
πŸ” WHY VSTM SCORES 36/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (44% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime Γ— Technicals: 83% of 52W Range β€’ RSI-14 at 61.2 (BULLISH MOMENTUM)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
28
Grade E$7.45+25.4% Next Q
Q2 (-2Q)
31
Grade E$9.34+8.1% Next Q
Q3 (-1Q)
33
Grade E$10.10-5% Next Q
Current
36
Grade D-$9.59-8.3% Hist 90D Ξ±
Trajectory: E (28) β†’ D- (36)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a VSTM Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While VSTM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.27) and Max Pain ($10.07) forces dealer call-delta covering toward $11.36.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VSTMβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œVSTM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

VSTM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (VSTM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on VSTM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VSTM)

  • βœ“Walkthrough of VSTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
VSTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +61.18%β–² ASCENDING CHANNEL
2026-11-03O $9.66H $9.75L $9.59C $9.59VOL 2.41M
RES: $10.39SUP: $7.01SMA50: $8.27SMA200: $6.20
$10.73$8.75$6.77$4.79$2.82RES $10.39SUP $7.01$9.592026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VSTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ VSTM Butterfly Map β†’ + Track VSTM β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +209.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VSTM today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for VSTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VSTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VSTM)

Health Care Rank #561 of 1015 βš”οΈ AMPH vs VSTM Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (VSTM vs. AMPH, RAPP, SNDX, SLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Verastem Inc. (VSTM) ranks #561 by composite RQD confidence (36/100, grade D-) and #334 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with VSTM at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VSTM ACTIVE
Verastem Inc.
D- 36/100 β€” β€” -35.0% -1.64% $1.18B Benchmark Subject
AMPH
Amphastar Pharmaceuticals Inc.
B 72/100 11.7x 49.5% 9.0% -2.49% $1.18B /amph-vs-vstm β†’
RAPP
Rapport Therapeutics Inc.
E 30/100 β€” β€” -22.9% +0.32% $1.20B /rapp-vs-vstm β†’
SNDX
Syndax Pharmaceuticals Inc.
E 17/100 β€” β€” -35.0% -4.03% $1.22B /sndx-vs-vstm β†’
SLN
Silence Therapeutics Plc American Depository Share
D 44/100 β€” 61.5% -35.0% +0.05% $1.23B /sln-vs-vstm β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001526119 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verastem Inc. (VSTM) reported GAAP revenue of $30.9M (+209.1% vs. FY2024 revenue of $10.0M , and -88.0% cumulative change since FY2023) , GAAP net income of -$209.5M, operating cash flow of -$137.5M, and free cash flow of -$137.5M (-31.2% YoY). On the balance sheet, VSTM closed FY2025 with $246.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $30.9M -$209.5M -$137.5M -$137.5M $246.4M β€”
FY2024 (FY) 2024-12-31 $10.0M -$130.6M -$104.8M -$104.8M $101.5M β€”
FY2023 (FY) 2023-12-31 $257.8M -$87.4M -$86.5M -$86.5M β€” β€”

3. VSTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Verastem Inc. (NASDAQ: VSTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.59 (-1.64% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VSTM ranks #561 in composite RQD confidence.

How does VSTM compare to AMPH and RAPP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, AMPH (Amphastar Pharmaceuticals Inc.) holds a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VSTM?

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VSTM trading relative to its 50-day, 200-day, and 52-week technical levels?

VSTM last traded at $9.59 (-1.64% on volume of 2,112,810 shares), positioning the stock +15.96% above its 50-day simple moving average ($8.27) and +54.68% above its 200-day simple moving average ($6.20). Across its 52-week range of $3.43 to $10.82, VSTM sits at the 83.4% percentile with a 14-day RSI of 61.2 (BULLISH MOMENTUM) and an implied next-earnings move of Β±12.5% ($8.39 to $10.79).

Direct Sub-Reports: VSTM RQD Cockpit VSTM 12M Forecast VSTM Earnings & Move VSTM Dividends & DRIP VSTM Insiders & 13F VSTM Whale Options VSTM Profit Sankey VSTM News & Why
ROARABLE RATING BRIEF β€’ RQD 36/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

VSTM β€” Verastem Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Verastem Inc. (VSTM) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.59 (-1.64% 1D, market capitalization $1.18B).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -11.72%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Verastem Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Verastem Inc. (VSTM) reported $30.9M in annual revenue (up from $10.0M in FY2024, +209.1% YoY) and -$209.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($257.8M revenue, -$87.4M net income) through FY2025, VSTM scaled operating cash flow to -$137.5M and free cash flow to -$137.5M, backed by $246.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 36/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -11.72% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $3.43 – $10.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VSTM carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can VSTM sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $30.9M and free cash flow of -$137.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VSTM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VSTM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Verastem Inc. (VSTM) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to VSTM Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VSTM Bull vs. Bear Conversation Board β€” What's Your Call at $9.59?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VSTM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VSTM:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $11.21 (+15.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning score 16/20 in the RQD rating, and analysts are cited as expecting upside after stro

Institutional accumulation and options positioning score 16/20 in the RQD rating, and analysts are cited as expecting upside after strong trial data.. When you look under the hood at VSTM, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $10.82. My 12M target is $11.21.

ArenaChamp_24 πŸ‚ BULL

@SiliconVal_Bull Agree on the RQD 36/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.75 and keeping dry powder in case we test $9.07.

RI RiskArb_Desk RQD DEBATE OPENER β€’ Hedged Event Driven 🐻 BEARISH 🎯 Target: $8.09 (-17.0%)
Spot @ $9.75

With an Altman Z of 0.2, Piotroski F of 3/9, FY 2025 net loss of -$209.5M, and a $250 Million equity offering, the balance sheet and ca

Careful chasing VSTM at $9.75. With an Altman Z of 0.2, Piotroski F of 3/9, FY 2025 net loss of -$209.5M, and a $250 Million equity offering, the balance sheet and cash burn are the dominant risks.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $8.09 on multiple compression.

LIVE TAPE